Skip to main content
. Author manuscript; available in PMC: 2024 Mar 29.
Published in final edited form as: Am J Hematol. 2023 Apr 5;98(6):900–912. doi: 10.1002/ajh.26919

FIGURE 1.

FIGURE 1

(A) Median PFS for the entire cohort of 539 patients was 17 months (95% CI 13–22 months). PFS at 36 months was 37% (955 CI 33–42). (B) Median OS was 43 months (95% CI 31–56 months). OS at 36 months was 53% (95% CI 48–57). (C). PFS for each of the three most common induction regimens, adjusted for significant pre-treatment variables. PFS was highest for patients treated with the MTR regimen. (D). OS for each of the three most common induction regimens, adjusted for significant pre-treatment variables. OS was highest for patients treated with the MTR regimen.